Human NK cells activated by EBV⁺ lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells

References

• Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26:1324-37; PMID:17322918; http://dx.doi.org/10.1038/sj.onc.1210220
   PubMed Web of Science ®Google Scholar
• Lindner SE, Wissler M, Grunder A, Aumann K, Ottina E, Peintner L, Brauns-Schubert P, Preiss F, Herzog S, Borner C, et al. Increased leukocyte survival and accelerated onset of lymphoma in the absence of MCL-1 S159-phosphorylation. Oncogene 2013; 33:5221-5224; PMID:24213575; http://dx.doi.org/10.1038/onc.2013.469
   PubMed Web of Science ®Google Scholar
• McKeithan TW, Rowley JD, Shows TB, Diaz MO. Cloning of the chromosome translocation breakpoint junction of the t(14;19) in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1987; 84:9257-60; PMID:3122218; http://dx.doi.org/10.1073/pnas.84.24.9257
   PubMed Web of Science ®Google Scholar
• Traver D, Akashi K, Weissman IL, Lagasse E. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 1998; 9:47-57; PMID:9697835; http://dx.doi.org/10.1016/S1074-7613(00)80587-7
   PubMed Web of Science ®Google Scholar
• Zhou P, Qian L, Bieszczad CK, Noelle R, Binder M, Levy NB, Craig RW. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood 1998; 92:3226-39; PMID:9787159
   PubMed Web of Science ®Google Scholar
• Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, Izon DJ, Zuber J, Rappaport AR, Herold MJ, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 2012; 26:120-5; PMID:22279045; http://dx.doi.org/10.1101/gad.182980.111
   PubMed Web of Science ®Google Scholar
• Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008; 111:846-55; PMID:17928528; http://dx.doi.org/10.1182/blood-2007-05-089037
   PubMed Web of Science ®Google Scholar
• Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang HG, Zhang X, Bullrich F, Croce CM, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998; 91:3379-89; PMID:9558396
   PubMed Web of Science ®Google Scholar
• Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463:899-905; PMID:20164920; http://dx.doi.org/10.1038/nature08822
   PubMed Web of Science ®Google Scholar
• Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:269-81; PMID:22437939; http://dx.doi.org/10.1038/nri3191
   PubMed Web of Science ®Google Scholar
• Villalba M, Rathore MG, Lopez-Royuela N, Krzywinska E, Garaude J, Allende-Vega N. From tumor cell metabolism to tumor immune escape. Int J Biochem Cell Biol 2013; 45:106-13; PMID:22568930; http://dx.doi.org/10.1016/j.biocel.2012.04.024
   PubMed Web of Science ®Google Scholar
• Pardo J, Wallich R, Martin P, Urban C, Rongvaux A, Flavell RA, Müllbacher A, Borner C, Simon MM. Granzyme B-induced cell death exerted by ex vivo CTL: discriminating requirements for cell death and some of its signs. Cell Death Differ 2008; 15:567-79; PMID:18064039; http://dx.doi.org/10.1038/sj.cdd.4402289
   PubMed Web of Science ®Google Scholar
• Roder JC, Karre K, Kiessling R. Natural killer cells. Prog Allergy 1981; 28:66-159; PMID:6166015
   PubMedGoogle Scholar
• Herberman RB, Holden HT. Natural cell-mediated immunity. Adv Cancer Res 1978; 27:305-77; PMID:356546; http://dx.doi.org/10.1016/S0065-230X(08)60936-7
   PubMedGoogle Scholar
• Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990; 11:237-44; PMID:2201309; http://dx.doi.org/10.1016/0167-5699(90)90097-S
   PubMedGoogle Scholar
• Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22:633-40; PMID:11698225; http://dx.doi.org/10.1016/S1471-4906(01)02060-9
   PubMed Web of Science ®Google Scholar
• Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9:495-502; PMID:18425106; http://dx.doi.org/10.1038/ni1581
   PubMed Web of Science ®Google Scholar
• Bottino C, Moretta L, Moretta A. NK cell activating receptors and tumor recognition in humans. Curr Top Microbiol Immunol 2006; 298:175-82; PMID:16323416; http://dx.doi.org/10.1007/3-540-27743-9_9
   PubMed Web of Science ®Google Scholar
• Chan CJ, Andrews DM, Smyth MJ. Can NK cells be a therapeutic target in human cancer? Eur J Immunol 2008; 38:2964-8; PMID:18979512; http://dx.doi.org/10.1002/eji.200838764
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Mancusi A, Burchielli E, Perruccio K, Aversa F, Martelli MF, Velardi A. Natural killer cell recognition of missing self and haploidentical hematopoietic transplantation. Semin Cancer Biol 2006; 16:404-11; PMID:16916611; http://dx.doi.org/10.1016/j.semcancer.2006.07.007
   PubMed Web of Science ®Google Scholar
• Willemze R, Rodrigues CA, Labopin M, Sanz G, Michel G, Socie G, Rio B, Sirvent A, Renaud M, Madero L, et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009; 23:492-500; PMID:19151783; http://dx.doi.org/10.1038/leu.2008.365
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, Stern M, Pende D, Perruccio K, Burchielli E, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007; 110:433-40; PMID:17371948; http://dx.doi.org/10.1182/blood-2006-07-038687
   PubMed Web of Science ®Google Scholar
• Velardi A. Natural killer cell alloreactivity 10 years later. Curr Opin Hematol 2012; 19:421-6; PMID:22954728; http://dx.doi.org/10.1097/MOH.0b013e3283590395
   PubMed Web of Science ®Google Scholar
• Fuchs EJ, Huang XJ, Miller JS. HLA-haploidentical stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2009; 16:S57-63; PMID:19892024; http://dx.doi.org/10.1016/j.bbmt.2009.10.032
   PubMedGoogle Scholar
• Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, Moreno A, Dupont B, Hsu KC, Baxter-Lowe LA, et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 2008; 143:641-53; PMID:18950462; http://dx.doi.org/10.1111/j.1365-2141.2008.07340.x
   PubMed Web of Science ®Google Scholar
• Curti A, Ruggeri L, D'Addio A, Bontadini A, Dan E, Motta MR, Trabanelli S, Giudice V, Urbani E, Martinelli G, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 2011; 118:3273-9; PMID:21791425; http://dx.doi.org/10.1182/blood-2011-01-329508
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Bell T, Pui CH, Leung W. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010; 28:955-9; PMID:20085940; http://dx.doi.org/10.1200/JCO.2009.24.4590
   PubMed Web of Science ®Google Scholar
• Cho D, Campana D. Expansion and activation of natural killer cells for cancer immunotherapy. Korean J Lab Med 2009; 29:89-96; PMID:19411773; http://dx.doi.org/10.3343/kjlm.2009.29.2.89
   PubMedGoogle Scholar
• Perussia B, Ramoni C, Anegon I, Cuturi MC, Faust J, Trinchieri G. Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines. Nat Immun Cell Growth Regul 1987; 6:171-88; PMID:2960890
   PubMedGoogle Scholar
• Sanchez-Martinez D, Krzywinska E, Rathore MG, Saumet A, Cornillon A, Lopez-Royuela N, Martínez-Lostao L, Ramirez-Labrada A, Lu ZY, Rossi JF, et al. All-trans retinoic acid (ATRA) induces miR-23a expression, decreases CTSC expression and granzyme B activity leading to impaired NK cell cytotoxicity. Int J Biochem Cell Biol 2014; 49:42-52; PMID:24440757; http://dx.doi.org/10.1016/j.biocel.2014.01.003
   PubMed Web of Science ®Google Scholar
• Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, Eldridge P, Leung WH, Campana D. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009; 69:4010-7; PMID:19383914; http://dx.doi.org/10.1158/0008-5472.CAN-08-3712
   PubMed Web of Science ®Google Scholar
• Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton L, Maiti SN, Huls MH, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLOS ONE 2012; 7:e30264; PMID:22279576; http://dx.doi.org/10.1371/journal.pone.0030264
   PubMed Web of Science ®Google Scholar
• Childs RW, Berg M. Bringing natural killer cells to the clinic: ex vivo manipulation. HEMATOLOGY 2013; 2013:234-46; PMID:24319186; http://dx.doi.org/10.1182/asheducation-2013.1.234
   PubMedGoogle Scholar
• Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, Anderson D, Eisenmann J, Grabstein K, Caligiuri MA. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994; 180:1395-403; PMID:7523571; http://dx.doi.org/10.1084/jem.180.4.1395
   PubMed Web of Science ®Google Scholar
• Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lopez-Botet M, et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A 1998; 95:5199-204; PMID:9560253; http://dx.doi.org/10.1073/pnas.95.9.5199
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Geraghty DE, Koller BH, Orr HT, DeMars R. Transfer and expression of three cloned human non-HLA-A,B,C class I major histocompatibility complex genes in mutant lymphoblastoid cells. Proc Natl Acad Sci U S A 1988; 85:227-31; PMID:3257565; http://dx.doi.org/10.1073/pnas.85.1.227
   PubMed Web of Science ®Google Scholar
• Kurago ZB, Lutz CT, Smith KD, Colonna M. NK cell natural cytotoxicity and IFN-gamma production are not always coordinately regulated: engagement of DX9 KIR+ NK cells by HLA-B7 variants and target cells. J Immunol 1998; 160:1573-80; PMID:9469412
   PubMed Web of Science ®Google Scholar
• Núñez D, Domingo MP, Sánchez-Martínez D, Cebolla V, Chiou A, Velázquez-Campoy A, Pardo J,, Galvez EM, Recombinant production of human ICAM-1 chimeras by single step on column refolding and purification. Proc Biochem 2013; 48:708-15.
   Web of Science ®Google Scholar
• Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankarlo D, Luo X, Cooley S, Verneris M, Walcheck B, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 2013; 121:3599-608; PMID:23487023; http://dx.doi.org/10.1182/blood-2012-04-425397
   PubMed Web of Science ®Google Scholar
• Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, Augugliaro R, Moretta L, Moretta A. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998; 187:2065-72; PMID:9625766; http://dx.doi.org/10.1084/jem.187.12.2065
   PubMed Web of Science ®Google Scholar
• De Miguel D, Basanez G, Sanchez D, Malo PG, Marzo I, Larrad L, Naval J, Pardo J, Anel A, Martinez-Lostao L. Liposomes decorated with Apo2L/TRAIL overcome chemoresistance of human hematologic tumor cells. Mol Pharm 2013; 10:893-904; PMID:23331277; http://dx.doi.org/10.1021/mp300258c
   PubMed Web of Science ®Google Scholar
• Sedelies KA, Ciccone A, Clarke CJ, Oliaro J, Sutton VR, Scott FL, Silke J, Susanto O, Green DR, Johnstone RW, et al. Blocking granule-mediated death by primary human NK cells requires both protection of mitochondria and inhibition of caspase activity. Cell Death Differ 2008; 15:708-17; PMID:18202705; http://dx.doi.org/10.1038/sj.cdd.4402300
   PubMed Web of Science ®Google Scholar
• Gyrd-Hansen M, Darding M, Miasari M, Santoro MM, Zender L, Xue W, Tenev T, da Fonseca PC, Zvelebil M, Bujnicki JM, et al. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat Cell Biol 2008; 10:1309-17; PMID:18931663; http://dx.doi.org/10.1038/ncb1789
   PubMed Web of Science ®Google Scholar
• Locatelli F, Pende D, Mingari MC, Bertaina A, Falco M, Moretta A, Moretta L. Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Front Immunol 2013; 4:15; PMID:23378843; http://dx.doi.org/10.3389/fimmu.2013.00015
   PubMed Web of Science ®Google Scholar
• Berg M, Lundqvist A, McCoy P, Jr., Samsel L, Fan Y, Tawab A, Childs R. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009; 11:341-55; PMID:19308771; http://dx.doi.org/10.1080/14653240902807034
   PubMed Web of Science ®Google Scholar
• Kay NE, Zarling JM. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 1984; 63:305-9; PMID:6607080
   PubMed Web of Science ®Google Scholar
• Veuillen C, Aurran-Schleinitz T, Castellano R, Rey J, Mallet F, Orlanducci F, Pouyet L, Just-Landi S, Coso D, Ivanov V, et al. Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy. J Clin Immunol 2011; 32:632-46; PMID:22318393; http://dx.doi.org/10.1007/s10875-011-9624-5
   PubMed Web of Science ®Google Scholar
• Mahrus S, Craik CS. Selective chemical functional probes of granzymes A and B reveal granzyme B is a major effector of natural killer cell-mediated lysis of target cells. Chem Biol 2005; 12:567-77; PMID:15911377; http://dx.doi.org/10.1016/j.chembiol.2005.03.006
   PubMed Web of Science ®Google Scholar
• Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, Yun GH, Fautsch SK, McKenna D, Le C. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105:3051-7; PMID:15632206; http://dx.doi.org/10.1182/blood-2004-07-2974
   PubMed Web of Science ®Google Scholar
• Kroger N, Zabelina T, Berger J, Duske H, Klyuchnikov E, Binder T, Stübig T, Hilde-brandt Y, Atanackovic D, Alchalby H, et al. Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia 2011; 25:1657-61; PMID:21647155; http://dx.doi.org/10.1038/leu.2011.138
   PubMed Web of Science ®Google Scholar
• Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15:1126-32; PMID:19228717; http://dx.doi.org/10.1158/1078-0432.CCR-08-0144
   PubMed Web of Science ®Google Scholar
• Vandenberg CJ, Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 2013; 121:2285-8; PMID:23341542; http://dx.doi.org/10.1182/blood-2013-01-475855
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19:202-8; PMID:23291630; http://dx.doi.org/10.1038/nm.3048
   PubMed Web of Science ®Google Scholar
• Vogler M, Hamali HA, Sun XM, Bampton ET, Dinsdale D, Snowden RT, Dyer MJ, Goodall AH, Cohen GM. BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood 2011; 117:7145-54; PMID:21562047; http://dx.doi.org/10.1182/blood-2011-03-344812
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097-100; PMID:11896281; http://dx.doi.org/10.1126/science.1068440
   PubMed Web of Science ®Google Scholar